Fig. 2From: Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case seriesBest Response of on-target lesions. Changes in the injectable lesions for each patient are shown as waterfall plot. CR, complete response. Cutaneous lesions are shown in blue and subcutaneous lesions are shown in red. CR, complete responseBack to article page